Name	Ji Hyun Lee
Current Position & Affiliation	Professor, Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine
Country	Republic of Korea
Major Field	Multiple myeloma, Acute lymphoblastic leukemia, Lymphoma, CAR T-cell therapy, Hematopoietic Stem Cell Transplantation, Thrombosis and hemostasis

Educational Background

- PhD in Medicine (Hematology–Oncology): Dong-A University College of Medicine, Busan, Korea (2010–2013)
- Master of Medicine (Internal Medicine): Dong-A University College of Medicine, Busan, Korea (2008–2010)
- Doctor of Medicine: Dong-A University College of Medicine, Busan, Korea (2000–2006)
- Clinical Clerkship: Brigham and Women's Hospital, Harvard Medical School, Boston, USA (2005)

Professional Experience

- Professor, Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Dong-A University Hospital (2025-present)
- Deputy Quality Manager, CAR T-cell Therapy Center, Dong-A University Hospital (2024–present)
- Associate Professor, Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Dong-A University Hospital (2020-2025)
- Assistant Professor, Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Dong-A University Hospital (2014-2020)
- Clinical Fellow / Instructor, Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University Hospital (2011-2014)

Other Experience and Professional Memberships

- Member, International Myeloma Working Group (IMWG) (2024–current)
- Member, Asian Myeloma Network (2024–current)
- Deputy Chair, CAR T-cell Committee, Korean Society of Hematology (2022–current)
- Scientific Committee Member, Korean Society of Hematology (2019–current)
- Scientific Committee Member, Korean Society of Blood and Marrow Transplantation (2018-current)
- Editorial Board Member, Cardio-Oncology Working Group, Korean Society of Cardiology (2024-current)
- Director of Public Relations, Korean Society of Thrombosis and Hemostasis (2025-current)

Main Scientific Publications

1. Jung SH, Kim D, Lee JJ, Kim K, Min CK, Lee JH, Lee WS, **Lee JH**, Lee GW, Kim MK, Shin HJ, Kim HJ, Yi JH, Lee HS. A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-

VRD) in patients with Waldenström's macroglobulinaemia (KMM1803). *Br J Haematol*. 2025 Nov 28. doi:10.1111/bjh.70261. [Online ahead of print.]

2. Yi JH, Park SS, Min CK, Lee JH, Eom HS, **Lee JH**, Kim K. Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.
   Int J Hematol. 2025 Oct 24. doi:10.1007/s12185-025-04087-w. [Online ahead of print.]
3. Baek DW, Sohn SK, Jung SH, Song GY, Song IC, Koh JS, Shin HJ, Kim DY, Kim SH, **Lee JH,** Lim SN, Lee WS, Do YR, Kim MK, Park YH, Eom HS, Jung KS, Kong JH, Moon JH; Adult Acute Lymphoblastic Leukemia Working Party, Korean Society of Hematology.
   Survival benefits of early treatment with blinatumomab in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. *Clin Lymphoma Myeloma Leuk*. 2025;25(12):e1160-e1172.e8. doi:10.1016/j.clml.2025.09.004.
4. Lee J, Choi E, Han B, Kim JA, Jung D, Kim KH, Oh SY, Kim SH, Ha KS, Kim JH, **Lee JH**, Cho D, Doh J, Kim SH. Tumor-priming $CD8^+$ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma. *Exp Hematol Oncol*. 2025;14:116. doi:10.1186/s40164-025-00707-7.
5. Baek DW, Moon JH, Lee JH, Kang KW, Lee HS, Eom HS, Lee E, Lee JH, Lee JO, Park SK, Kim SJ, Koh Y, Won JH, **Lee JH**, Park JS, Jo JC, Mun YC, Yang DH, Song GY, Lim SN, Sohn SK; Korean Society of Blood and Marrow Transplantation. A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry. *Blood Res*. 2025;60(1):44. doi:10.1007/s44313-025-00092-4.
6. Yi JH, **Lee JH**, Jung SH, Lee JH, Lee JY, Kim K, Park SS, Min CK, Choi YS, Kim MK, Yhim HY, Yoon DH. Real-world efficacy and safety of teclistamab for patients with relapsed or refractory multiple myeloma: nationwide retrospective analysis of the named patient program in Korea. *Cancer Res Treat*. 2025 Jul 30. doi:10.4143/crt.2025.399. Online ahead of print.
7. Kim DY, Min CK, Eom HS, Jung J, Kim K, **Lee JH**, Yoo KH, Lee JY, Byun JM, Kim SH, Lee JH, Cho HJ, Lee SM, Do YR, Park S, Lee J, Lee SS, Kang HJ, Park YH, Lim SN, Shin HJ; Korean Multiple Myeloma Working Party. Real-world comparison of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma: KMM2004 study. *Clin Lymphoma Myeloma Leuk*. 2025;25(12):873-884. doi:10.1016/j.clml.2025.06.006.
8. Im S, Choi SM, Kim YY, Jeong DJ, Um JH, Lee KM, Yoo E, Cho JH, **Lee JH**, Yun J. A novel isoquinoline mitophagy inducer ameliorates paclitaxel-induced peripheral neuropathy in *Drosophila* and mouse models. *Sci Rep*. 2025;15:20960. doi:10.1038/s41598-025-04178-y.
9. **Lee JH**, Oh SY, Lee TG, Shin S, Lee ST, Kim N, Pak MK, Yoon SS, Koh Y, Byun JM, Yoon DH, Jo JC, Yang DH, Ahn SY, Eom HS, Lee H, Lee JY, Won JH, Yhim HY, Lee HS, Kim WS, Kim SJ. Comprehensive clinico-genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm. *British Journal of Haematology*. 2025 Apr;206(4):1228-1232.
10. **Lee JH**, Choi J, Min C-K, Park S-S, Jo J-C, Lee YJ, Kim JS, Eom H-S, Jung J , Moon JH, Cho HJ, Lee M-W, Yoon S-S, Byun JM, Lee JH, Lee J-J, Jung S-H, Shin H-J, Kim DY, Yi JH, Lee S-S, Do YR, Yoon DH, Cho H, Lee WS, Lee HS, Uhm J, Kim HJ, Jang HR, Kim S-H, and Kim K. Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone

combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study. Haematologica. 2024 Nov 1;109(11):3681-3692.